Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance

PURPOSE: To evaluate the efficacy and safety of TACE combined with regorafenib plus PD-1 inhibitor as a second-line therapy for hepatocellular carcinoma after sorafenib resistance. MATERIALS AND METHODS: The clinical data of 76 patients with hepatocellular carcinoma who were drug-resistant to sorafe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Xinhua, Xu, Qingyu, You, Ran, Yin, Guowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940502/
https://www.ncbi.nlm.nih.gov/pubmed/36815093
http://dx.doi.org/10.2147/JHC.S399874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940502/
https://www.ncbi.nlm.nih.gov/pubmed/36815093
http://dx.doi.org/10.2147/JHC.S399874

Ejemplares similares